3/8/2024

Moxifloxacin Tablets

Products Affected - Description

- Moxifloxacin hydrochloride oral tablet, Major, 400 mg, unit-dose blister pack, 30 count, NDC 00904-6406-04
- Moxifloxacin hydrochloride oral tablet, Major, 400 mg, unit-dose blister pack, 50 count, NDC 00904-6406-06
- Moxifloxacin hydrochloride oral tablet, Rising Pharmaceuticals, 400 mg, bottle, 30 count, NDC 57237-0156-30
- Moxifloxacin hydrochloride oral tablet, Teva, 400 mg, bottle, 30 count, NDC 00093-7387-56

Reason for the Shortage

- Major did not provide a reason for the shortage.
- Rising did not provide a reason for the shortage.
- Teva did not provide a reason for the shortage.
- Aurobindo refuses to provide availability information.

Available Products

- There is insufficient supply for usual ordering

Estimated Resupply Dates

- Major has moxifloxacin 400 mg tablets in 30 count and 50 count unit-dose packages on back order and the company cannot estimate a release date.
- Rising has moxifloxacin 400 mg tablets in 30 count bottles on intermittent back order and the company is releasing supplies as they become available.
- Teva has moxifloxacin 400 mg tablets in 30 count bottles on back order and the company cannot estimate a release date.

Updated

Updated March 8, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. Created December 6, 2023 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.